Apiconisis

Reference number
Coordinator Apiconisis AB
Funding from Vinnova SEK 400 000
Project duration December 2012 - July 2013
Status Completed

Purpose and goal

We expected to get ten new projects and completed three. We expected this to give us enough references on relevant targets for initiating collaboration with Big Pharma. We conducted three projects successfully and brought in an additional 6 projects with leading institutions around Europe. This has given us the experimental data and references to reach the pharmaceutical companies. In the current situation we are in final discussions with two pharmaceutical companies in Belgium and the United States.

Results and expected effects

The expected effect of the project was to attract the industry. We believe we have been successful in this aspect. We now have a large material and credentials to be taken seriously.

Approach and implementation

We have been to three conferences in Stockholm, London and San Diego. We have undergone a drug discovery screening training in Germany and sales training with STING. In addition, our CEO has undergone leadership training. We have developed software along with a U.S. institution. We have developed a new brand and sought protection with help from Bergenstråhle & Lindvall (B & L). Patent Strategies have been performed in consultation with Forskarpatent, AWA Patent and B & L. A plan for future funding has been prepared together with a business angel.

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 25 November 2019

Reference number 2012-04360

Page statistics